← Leaderboards
Hongmin Li
Wadsworth Center
$16,065,705
Attributed
$20,353,656
Total exposure
21
Grants
20
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,353,656 · 21
By mechanism
R01$15,254,001 · 6
R21$3,467,382 · 8
R56$717,154 · 2
R41$599,970 · 1
S10$305,489 · 1
P41$9,660 · 3
Top collaborators
- Dorina Avram5 shared
- Arun K Ghosh5 shared
- Laura D. Kramer5 shared
- David A Lawrence1 shared
- David M Lemaster1 shared
Most similar at Wadsworth Center
Same institution · by research overlap
- Marlene Belfort$19,518,414
- Laura D. Kramer$8,574,267
- David A Lawrence$9,918,872
Others in their field
Top investigators on “Innovation”
- David R. Weir · University Of Michigan At Ann Arbor$382,307,654
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$319,874,172
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$311,654,401
- Richard A Gibbs · Baylor College Of Medicine$300,634,418
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Judith S. Currier · University Of California Los Angeles$271,752,220
Research focus
InnovationStructureIn VivoCellsEnzymesBindingComplexHigh Throughput ScreeningAffinityScreeningLeadIn VitroBaseMutagenesisInfectionAnalogCombatDisease OutbreaksFlavivirusToxic EffectEnsureDrug KineticsProteinsBiochemical
Grant awards (50)
Development of Inhibitors Targeting Flavivirus Methyltransferase$767,382
R01 · FY2025 · AI · contact PI
High throughput screening assays to identify chemical probes targeting Hectd3, an E3 ubiquitin ligase implicated in multiple sclerosis$763,630
R01 · FY2025 · AI · contact PI
Development of Inhibitors Against SARS CoV-2 NSP16 Methyltransferase$299,985
R41 · FY2025 · AI · contact PI
High throughput screening assays to identify chemical probes targeting Hectd3, an E3 ubiquitin ligase implicated in multiple sclerosis$787,248
R01 · FY2024 · AI · contact PI
Development of Inhibitors Targeting Flavivirus Methyltransferase$767,382
R01 · FY2024 · AI · contact PI
Development of Inhibitors Against SARS CoV-2 NSP16 Methyltransferase$299,985
R41 · FY2024 · AI · contact PI
High throughput screening assays to identify chemical probes targeting Hectd3, an E3 ubiquitin ligase implicated in multiple sclerosis$787,248
R01 · FY2023 · AI · contact PI
Development of Inhibitors Targeting Flavivirus Methyltransferase$767,382
R01 · FY2023 · AI · contact PI
Acquisition of a MicroCal PEAQ-ITC Automated$305,489
S10 · FY2023 · OD · contact PI
High throughput screening assays to identify chemical probes targeting Hectd3, an E3 ubiquitin ligase implicated in multiple sclerosis$787,248
R01 · FY2022 · AI · contact PI
High throughput screening of the Prp8 intein splicing inhibitors for pathogenic fungi$569,343
R01 · FY2022 · AI · contact PI
High throughput screening of orthosteric inhibitors of flavivirus protease$550,021
R01 · FY2022 · AI · contact PI
High throughput screening assays to identify chemical probes targeting Hectd3, an E3 ubiquitin ligase implicated in multiple sclerosis$813,998
R01 · FY2021 · AI · contact PI
High throughput screening of the Prp8 intein splicing inhibitors for pathogenic fungi$582,718
R01 · FY2021 · AI · contact PI
High throughput screening of orthosteric inhibitors of flavivirus protease$563,396
R01 · FY2021 · AI · contact PI
High throughput screening of the Prp8 intein splicing inhibitors for pathogenic fungi$590,586
R01 · FY2020 · AI · contact PI
High throughput screening of orthosteric inhibitors of flavivirus protease$571,217
R01 · FY2020 · AI · contact PI
Discovery of therapeutics against Cryptococcosis by Repurposing Pharmaceutical Libraries$161,437
R21 · FY2020 · AI · contact PI
Discovery of therapeutics against Cryptococcosis by Repurposing Pharmaceutical Libraries$46,685
R21 · FY2020 · AI · contact PI
High throughput screening of the Prp8 intein splicing inhibitors for pathogenic fungi$664,586
R01 · FY2019 · AI · contact PI
High throughput screening of orthosteric inhibitors of flavivirus protease$571,217
R01 · FY2019 · AI · contact PI
Discovery of therapeutics against Cryptococcosis by Repurposing Pharmaceutical Libraries$233,323
R21 · FY2019 · AI · contact PI
Identification and characterization of allosteric inhibitors of Zika protease by targeting the NS2B conformational change$210,726
R21 · FY2019 · AI
Neutralizing nanobodies as therapeutics for Dengue virus$210,726
R21 · FY2019 · AI
High throughput screening of orthosteric inhibitors of flavivirus protease$324,263
R01 · FY2018 · AI · contact PI
Identification and characterization of allosteric inhibitors of Zika protease by targeting the NS2B conformational change$249,594
R21 · FY2018 · AI · contact PI
Neutralizing nanobodies as therapeutics for Dengue virus$249,594
R21 · FY2018 · AI · contact PI
In vivo efficacy studies of existing drugs re-purposed for flaviviruses in mouse models$214,086
R21 · FY2018 · AI · contact PI
New Use of Old Drugs for Zika Virus$211,514
R21 · FY2018 · AI · contact PI
High throughput screening of orthosteric inhibitors of flavivirus protease$523,552
R56 · FY2017 · AI · contact PI
In vivo efficacy studies of existing drugs re-purposed for flaviviruses in mouse models$238,240
R21 · FY2017 · AI · contact PI
New Use of Old Drugs for Zika Virus$235,470
R21 · FY2017 · AI · contact PI
Mechanism of MALT1 Regulation by a Novel Ubiquitin Ligase$190,534
R21 · FY2016 · AI · contact PI
Inhibition and mechanism of flavivirus methyltransferase$635,641
R01 · FY2015 · AI · contact PI
Mechanism of MALT1 Regulation by a Novel Ubiquitin Ligase$227,431
R21 · FY2015 · AI · contact PI
Inhibition and mechanism of flavivirus methyltransferase$635,641
R01 · FY2014 · AI · contact PI
Inhibition and mechanism of flavivirus methyltransferase$597,502
R01 · FY2013 · AI · contact PI
Inhibition and mechanism of flavivirus methyltransferase$661,641
R01 · FY2012 · AI · contact PI
Inhibition and mechanism of flavivirus methyltransferase$630,883
R01 · FY2011 · AI · contact PI
The West Nile virus methyltransferase$185,552
R21 · FY2010 · AI · contact PI
The West Nile virus methyltransferase$223,571
R21 · FY2009 · AI · contact PI
ANTI-RIBOSOMAL ANTIBODY STRUCTURE AND FUNCTION$3,654
P41 · FY2008 · RR · contact PI
Structure and Function of superantigens$193,602
R56 · FY2007 · AI · contact PI
ANTI-RIBOSOMAL ANTIBODY STRUCTURE AND FUNCTION$2,891
P41 · FY2007 · RR · contact PI
Human endogenous retrovirus superantigen HERV-K18$208,132
R21 · FY2006 · AI · contact PI
PSEUDOMONAS FLUORESCENS-ENCODED I2-LIKE T CELL ANTIGEN$3,115
P41 · FY2006 · RR · contact PI
Human endogenous retrovirus superantigen HERV-K18$170,767
R21 · FY2005 · AI
Superantigen-immunoreceptor interactions$293,921
R01 · FY2004 · AI
Superantigen-immunoreceptor interactions$287,883
R01 · FY2003 · AI
Superantigen-immunoreceptor interactions$282,024
R01 · FY2002 · AI